<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03311854</url>
  </required_header>
  <id_info>
    <org_study_id>NI-0501-06</org_study_id>
    <nct_id>NCT03311854</nct_id>
  </id_info>
  <brief_title>A Study to Investigate the Safety and Efficacy of Emapalumab, an Anti-IFN-gamma mAb in Patients With Systemic Juvenile Idiopathic Arthritis (sJIA) or Adult-onset Still's Disease (AOSD) Developing Macrophage Activation Syndrome/Secondary HLH (MAS/sHLH)</brief_title>
  <official_title>A Pilot, Open-label, Single Arm, Multicenter Study to Evaluate Safety, Tolerability, Pharmacokinetics and Efficacy of Intravenous Administrations of Emapalumab, an Anti-interferon Gamma (Anti-IFNγ) Monoclonal Antibody, in Patients With Systemic Juvenile Idiopathic Arthritis (sJIA) or Adult-onset Still's Disease (AOSD) Developing Macrophage Activation Syndrome/Secondary HLH (MAS/sHLH)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Swedish Orphan Biovitrum</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Swedish Orphan Biovitrum</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Macrophage Activation Syndrome (MAS) is a rare, life-threatening condition characterized by&#xD;
      uncontrolled hyperinflammation which may develop on the background of systemic Juvenile&#xD;
      Idiopathic Arthritis (sJIA) or Adult-onset Still's Disease (AOSD). Emapalumab is a monoclonal&#xD;
      antibody neutralizing interferon-gamma (IFN-gamma), a key cytokine which contributes to the&#xD;
      inflammation and tissue damage seen in MAS. The purpose of this study is to assess the&#xD;
      safety, tolerability and efficacy of emapalumab in sJIA or AOSD patients developing MAS,&#xD;
      presenting an inadequate response to high dose glucocorticoid treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 2, 2018</start_date>
  <completion_date type="Actual">May 19, 2020</completion_date>
  <primary_completion_date type="Actual">May 19, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence, severity, causality and outcomes of AEs (serious and nonserious).</measure>
    <time_frame>Up to Week 8</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Levels of emapalumab</measure>
    <time_frame>Up to week 8</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacodynamic Parameters</measure>
    <time_frame>Up to Week 8</time_frame>
    <description>Levels of INF-gamma, CXCL9 and CXCL10</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Levels (if any) of circulating antibodies against emapalumab to determine immunogenicity.</measure>
    <time_frame>Up to Week 8</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients achieving MAS remission by Week 8 after initiation of emapalumab treatment.</measure>
    <time_frame>Week 8</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to MAS remission.</measure>
    <time_frame>Up to Week 8</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients for whom glucocorticoids can be tapered and time to achievement of glucocorticoids tapering.</measure>
    <time_frame>Up to Week 8</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Up to Week 8</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients withdrawn from the study due to lack of efficacy.</measure>
    <time_frame>Up to Week 8</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Macrophage Activation Syndrome</condition>
  <condition>Lymphohistiocytosis, Hemophagocytic</condition>
  <condition>Arthritis, Juvenile</condition>
  <condition>Adult Onset Still Disease</condition>
  <arm_group>
    <arm_group_label>Emapalumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Emapalumab</intervention_name>
    <description>Emapalumab will be administered at the initial dose of 6 mg/kg by intravenous infusion. Emapalumab treatment will be continued at the dose of 3 mg/kg, every 3 days until study day 15, and then twice-a-week for an additional 2 weeks, i.e. until study day 28.</description>
    <arm_group_label>Emapalumab</arm_group_label>
    <other_name>Gamifant</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients of both genders&#xD;
&#xD;
          -  For sJIA patients: Confirmed sJIA diagnosis. For patients presenting with MAS in the&#xD;
             context of the onset of sJIA, high presumption of sJIA will suffice for&#xD;
             eligibility.For AOSD patients: confirmed AOSD diagnosis as per Yamaguchi criteria.&#xD;
&#xD;
          -  Diagnosis of active MAS.&#xD;
&#xD;
          -  Patient presenting an inadequate response to high dose i.v. glucocorticoid treatment.&#xD;
&#xD;
          -  Tocilizumab, TNF inhibitors and canakinumab, if administered, have to be discontinued&#xD;
             before emapalumab initiation.&#xD;
&#xD;
          -  Having received guidance on contraception for both male and female patients sexually&#xD;
             active and having reached puberty. Females of child-bearing potential require use of&#xD;
             highly effective contraceptive measures.Males with partners(s) of child-bearing&#xD;
             potential must agree to take appropriate precautions.&#xD;
&#xD;
          -  Informed consent provided by the patient (as required by local law), or by the&#xD;
             patient's legally authorized representative(s) with the assent of patients who are&#xD;
             legally capable of providing it, as applicable.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of suspected or confirmed primary HLH or HLH consequent to a neoplastic&#xD;
             disease.&#xD;
&#xD;
          -  Active mycobacteria (typical and atypical), Histoplasma Capsulatum, Shigella,&#xD;
             Salmonella, Campylobacter and Leishmania infections.&#xD;
&#xD;
          -  Clinical suspicion of latent tuberculosis.&#xD;
&#xD;
          -  Positive serology for HIV antibodies.&#xD;
&#xD;
          -  Presence of malignancy.&#xD;
&#xD;
          -  Patients who have another concomitant disease or malformation severely affecting the&#xD;
             cardiovascular, pulmonary, CNS, liver or renal function that in the opinion of the&#xD;
             Investigator may significantly affect likelihood to respond to treatment and/or&#xD;
             assessment of emapalumab safety.&#xD;
&#xD;
          -  History of hypersensitivity or allergy to any component of the study drug&#xD;
&#xD;
          -  Receipt of a BCG vaccine within 12 weeks prior to screening.&#xD;
&#xD;
          -  Receipt of live or attenuated live vaccines (other than BCG) within 6 weeks prior to&#xD;
             screening.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Cincinnati Children'S Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Necker-Enfants Malades, Unité d'Immunologie-hématologie et Rhumatologie pédiatriques</name>
      <address>
        <city>Paris</city>
        <zip>75743</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Pediatrico Bambino Gesù - UO Reumatologia</name>
      <address>
        <city>Rome</city>
        <zip>00165</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Sant Joan de Deu</name>
      <address>
        <city>Esplugues De Llobregat</city>
        <zip>08950</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Great Ormond Street Hospital</name>
      <address>
        <city>London</city>
        <zip>WC1N 3JH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Netherlands</country>
  </removed_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>August 21, 2017</study_first_submitted>
  <study_first_submitted_qc>October 11, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 17, 2017</study_first_posted>
  <disposition_first_submitted>May 12, 2021</disposition_first_submitted>
  <disposition_first_submitted_qc>May 12, 2021</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">May 28, 2021</disposition_first_posted>
  <last_update_submitted>June 22, 2021</last_update_submitted>
  <last_update_submitted_qc>June 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Juvenile</mesh_term>
    <mesh_term>Still's Disease, Adult-Onset</mesh_term>
    <mesh_term>Lymphohistiocytosis, Hemophagocytic</mesh_term>
    <mesh_term>Macrophage Activation Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>November 11, 2021</submitted>
  </pending_results>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

